A/H5N1 inactivated, split-virion influenza virus
Biological0.5 mL, Intramuscular
NCT Number: NCT00545701
The trial is a Phase II, open-label trial in healthy subjects aged 18 to 60 years to support the immunogenicity data from previous clinical studies.
Objectives:
* To describe the immune response 21 days after each vaccination. * To describe the safety profiles following each vaccination.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 2
Adelaide, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
0.5 mL, Intramuscular
Time frame: Day 42 post-vaccination 1
Sanofi Pasteur, a Sanofi Company
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00755274
Infections, Influenza
Norfolk, Virginia, United States
View Trial DetailsNCT00718146
Infections, Influenza
Edinburgh, United Kingdom
View Trial DetailsNCT00343681
Infections, Influenza
Allschwil, Switzerland
View Trial DetailsNCT00491257
Infections, Influenza
Edinburgh, United Kingdom
View Trial Details